{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tolerability&page=2",
    "query": {
      "condition": "Tolerability",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Tolerability&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T18:45:18.562Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00598078",
      "title": "Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Essential Tremor"
      ],
      "interventions": [
        {
          "name": "Sodium Oxybate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 19,
      "start_date": "2007-12",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2012-01-23",
      "last_synced_at": "2026-06-26T18:45:18.562Z",
      "location_count": 1,
      "location_summary": "Bingham Farms, Michigan",
      "locations": [
        {
          "city": "Bingham Farms",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00598078"
    },
    {
      "nct_id": "NCT00392015",
      "title": "NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Plasmodium Falciparum"
      ],
      "interventions": [
        {
          "name": "NMRC-M3V-Ad-PfCA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 59,
      "start_date": "2006-10-12",
      "completion_date": "2017-09-25",
      "has_results": true,
      "last_update_posted_date": "2021-05-21",
      "last_synced_at": "2026-06-26T18:45:18.562Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00392015"
    },
    {
      "nct_id": "NCT06087835",
      "title": "Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease With High Proteinuria"
      ],
      "interventions": [
        {
          "name": "Zibotentan/Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 1835,
      "start_date": "2023-11-07",
      "completion_date": "2027-02-18",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-06-26T18:45:18.562Z",
      "location_count": 64,
      "location_summary": "Huntsville, Alabama • Sun City West, Arizona • Bakersfield, California + 55 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Sun City West",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06087835"
    },
    {
      "nct_id": "NCT06550076",
      "title": "A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "TAK-279",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2099,
      "start_date": "2024-09-04",
      "completion_date": "2029-08-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-06-26T18:45:18.562Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06550076"
    },
    {
      "nct_id": "NCT01545076",
      "title": "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyneuropathy",
        "Polyradiculoneuropathy"
      ],
      "interventions": [
        {
          "name": "IgPro20 (low dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IgPro10",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IgPro20 (high dose)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2012-03",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2018-07-05",
      "last_synced_at": "2026-06-26T18:45:18.562Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01545076"
    },
    {
      "nct_id": "NCT06857617",
      "title": "This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Obesity and Overweight"
      ],
      "interventions": [
        {
          "name": "(Part C) MET097",
          "type": "BIOLOGICAL"
        },
        {
          "name": "(Part C) Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Metsera, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-04-01",
      "completion_date": "2025-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-06-26T18:45:18.562Z",
      "location_count": 3,
      "location_summary": "Anaheim, California • Cypress, California • Overland Park, Kansas",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06857617"
    },
    {
      "nct_id": "NCT07155668",
      "title": "A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "VRDN-003",
          "type": "DRUG"
        },
        {
          "name": "Autoinjector",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Viridian Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 87,
      "start_date": "2025-07-01",
      "completion_date": "2026-05-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-25",
      "last_synced_at": "2026-06-26T18:45:18.562Z",
      "location_count": 13,
      "location_summary": "Inglewood, California • Cape Coral, Florida • Kissimmee, Florida + 7 more",
      "locations": [
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Cape Coral",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07155668"
    },
    {
      "nct_id": "NCT01577550",
      "title": "Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "BI 655066 (very high i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo, i.v.",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (high s.c. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (low i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (high medium i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (very low i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (low s.c. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (high i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo, s.c.",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (low medium i.v. dose)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 39,
      "start_date": "2012-04",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2016-11-16",
      "last_synced_at": "2026-06-26T18:45:18.562Z",
      "location_count": 7,
      "location_summary": "Burbank, California • Miami, Florida • Port Orange, Florida + 4 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01577550"
    },
    {
      "nct_id": "NCT01372150",
      "title": "A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "desvenlafaxine succinate sustained release",
          "type": "DRUG"
        },
        {
          "name": "fluoxetine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "7 Years to 17 Years"
      },
      "enrollment_count": 340,
      "start_date": "2011-11-17",
      "completion_date": "2015-03-20",
      "has_results": true,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-06-26T18:45:18.562Z",
      "location_count": 41,
      "location_summary": "Dothan, Alabama • Goodyear, Arizona • Tucson, Arizona + 31 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01372150"
    },
    {
      "nct_id": "NCT06770491",
      "title": "A Phase 1 Study of Y-3 in US Healthy Volunteers.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Safety",
        "Tolerability",
        "Pharmacokinetic Study in Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Y-3 for injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurodawn Pharmaceutical Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-02-04",
      "completion_date": "2025-09-20",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-06-26T18:45:18.562Z",
      "location_count": 1,
      "location_summary": "Webster, Texas",
      "locations": [
        {
          "city": "Webster",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06770491"
    }
  ]
}